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Abstract
The	Solute	Carrier	15	(SLC15)	family	of	peptide	transporters,	alias	H+-coupled	oligopeptide
cotransporter	family,	is	a	group	of	membrane	transporters	known	for	their	key	role	in	the	cellular
uptake	of	di-	and	tripeptides	(di/tripeptides).	Of	its	members,	SLC15A1	(PEPT1)	chiefly	mediates
intestinal	absorption	of	luminal	di/tripeptides	from	overall	dietary	protein	digestion,	SLC15A2
(PEPT2)	mainly	allows	renal	tubular	reuptake	of	di/tripeptides	from	ultrafiltration	and	brain-to-blood
efflux	of	di/tripeptides	in	the	choroid	plexus,	SLC15A3	(PHT2)	and	SLC15A4	(PHT1)	interact	with
both	di/tripeptides	and	histidine,	e.g.	in	certain	immune	cells,	and	SLC15A5	has	unknown
physiological	function.	In	addition,	the	SLC15	family	of	peptide	transporters	variably	interacts	with	a
very	large	number	of	peptidomimetics	and	peptide-like	drugs.	It	is	conceivable,	based	on	the
currently	acknowledged	structural	and	functional	differences,	to	divide	the	SLC15	family	of	peptide
transporters	into	two	subfamilies	[3].
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